Jefferies picks Sai Life Sciences as top contract drug maker, hikes target price

Sai Life Sciences

12/03/2026 04:15

** Jefferies hikes Sai Life Sciences SAIE.NS PT to 1,300 rupees from 1,180 rupees, maintains "buy" rating, names it top contract research, development and manufacturing organisations (CRDMO) pick

** Brokerage highlights SAIE's "follow the molecule" model - pitching to clients from discovery to commercial lifecycle management

** Notes pure-play CRDMO with no unrelated divisions, contract for blockbuster oligo molecule "building blocks", no PE overhang

** Brokerage highlights strong growth outlook, healthy pipeline and balance sheet, overseas presence, room for upgrades in financial performance

** Stock above 50-day, 100-day, 200-day SMAs since Feb, indicating bullish sentiment

** Avg rating by 5 analysts is "strong buy", median PT 1,160 rupees, - data compiled by LSEG

** SAIE down 1.1% on broader market weakness at 1002.5 rupees

** YTD, SAIE up ~12%

(Reporting by Anuran Sadhu in Bengaluru)

((Anuran.Sadhu@thomsonreuters.com; +91 8697274436;))